2024-03-18T12:00:54-05:00 2023-06-30 520959934 ELLIN & TUCKER CHARTERED 400 EAST PRATT ST SUITE 200 BALTIMORE MD 21202 990 2022-07-01 742966731 SAN ANTONIO EYE BANK SANA 2106141209 9150 HUEBNER ROAD 105 SAN ANTONIO TX 78240 KENNETH J MAVERICK MD MEDICAL DIRECTOR 2106141209 2024-03-13 1 KENNETH MAVERICK MD 999009999 0 KIMBERLY A GOLDSBOROUGH-WILHELM P01589634 4107275735 2024-03-13 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z ARLO C TERRY MD 9150 HUEBNER ROAD 105 SAN ANTONIO TX 78240 4810398 0 X HTTPS://SAEYEBANK.ORG X 1965 TX RECOVERY, PROCESSING, AND DISTRIBUTION OF EYE TISSUE FOR TRANSPLANTATION. 11 11 0 11 0 0 10569 44870 4293240 3977297 301754 198240 0 0 4605563 4220407 13500 12500 0 0 2428670 2469204 0 0 14177 1757013 1638214 4199183 4119918 406380 100489 7846711 8892369 390986 1132130 7455725 7760239 RECOVERY, PROCESSING AND DISTRIBUTION OF EYE TISSUE FOR TRANSPLANTATION. 0 0 2853682 7200 3977297 MEDICAL SERVICES OF EYE BANKING (INCLUDING THE RECOVERY, PROCESSING, ANALYSIS, TESTING AND DISTRIBUTION OF DONATED CADAVERIC TISSUES) FOR TRANSPLANTATION. 131502 1100 RESEARCH - PROVIDING TISSUES FOR MEDICAL RESEARCH. THE EYE BANK DONATES EYE TISSUE FOR TRANSPLANTS, RESEARCH AND TEACHING FOR WHICH THEY INCUR PROCESSING COSTS. THEY SOMETIMES RECEIVE MINIMAL REIMBURSEMENT FOR THESE SERVICES. 491392 4200 PUBLIC HEALTH EDUCATION - EYE AND TISSUE DONOR OUTREACH AND DONOR ADVOCACY. 3476576 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 11 11 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 TX X ANNIE THOMPSON 2064147182 1200 6TH AVE STE 300 SEATTLE WA 98101 LT COL MATTHEW C CALDWELL MD CHAIRMAN 1.00 X X 0 0 0 KENNETH J MAVERICK MD MEDICAL DIRECTOR 1.00 X X 0 0 0 DANIEL JOHNSON MD DIRECTOR 1.00 X 0 0 0 CALVIN MEIN MD DIRECTOR 1.00 X 0 0 0 LISA MARTEN MD DIRECTOR 1.00 X 0 0 0 EVANGELISTA CHARISMA MD DIRECTOR 1.00 X 0 0 0 CHARLES REILLY MD DIRECTOR 1.00 X 0 0 0 JULIE C TSAI MD DIRECTOR 1.00 X 0 0 0 FERNANDO TRUJILLO MD DIRECTOR 1.00 X 0 0 0 JAMES LEHMANN MD DIRECTOR 1.00 X 0 0 0 ARLO C TERRY MD DIRECTOR 1.00 X 0 0 0 JIM S WAGNER EXECUTIVE DIRECTOR 40.00 X 192797 0 50824 192797 0 50824 1 0 1 0 CORNEAGEN 1200 6TH AVE STE 300 SEATTLE WA 98101 ADMINISTRATIVE SVCS 240000 1 44870 44870 TISSUE PROCESSING 541990 3977297 3977297 3977297 288231 288231 500000 584709 5282 -84709 -5282 -89991 -89991 4220407 3977297 0 198240 X 12500 12500 232396 220206 11209 981 1686864 1646247 31312 9305 53495 36911 16584 352328 243107 109221 144121 99443 44678 23894 23894 59535 59535 477883 237883 240000 46128 46128 53624 39877 13393 354 64381 54724 9657 178579 151792 26787 82409 67676 14372 361 1023 721 302 65254 48357 16863 34 15758 9849 5673 236 PROGRAM SUPPLIES 529326 526708 0 2618 PROGRAM SHIPPING 35281 30969 4024 288 MISCELLANEOUS 5139 3478 1661 0 4119918 3476576 629165 14177 X 125219 62813 20000 0 40031 123119 39639 28545 1005851 887777 188610 118074 7320662 8173958 112550 385860 7846711 8892369 327321 244574 63665 887556 390986 1132130 X 7455725 7760239 7455725 7760239 7846711 8892369 100489 204025 0 X X 0 1 X 1 0 X 5435 3351 302272 10569 44870 366497 4453456 3046132 3821348 4293240 3977297 19591473 4458891 3049483 4123620 4303809 4022167 19957970 0 654587 1149734 1728655 1820762 1611642 6965380 654587 1149734 1728655 1820762 1611642 6965380 12992590 166181 198750 176092 196061 288231 1025315 166181 198750 176092 196061 288231 1025315 4625072 3248233 4299712 4499870 4310398 20983285 0.61920 0.64160 0.04890 0.04890 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 546261 478124 68137 459590 409653 49937 118074 DUE TO CORNEAGEN 510168 OPERATING LEASE LIABILITY 377388 887556 X 4375464 204025 204025 4171439 54250 -5282 48968 4220407 4070950 5282 5282 4065668 54250 54250 4119918 PART X, LINE 2: FINANCIAL STATEMENT FOOTNOTE REGARDING FIN 48 (ASC 740) THE EYE BANK IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (CODE). IN ADDITION, THE INTERNAL REVENUE SERVICE DETERMINED THE EYE BANK IS NOT A PRIVATE ORGANIZATION WITHIN THE MEANING OF SECTION 509(A) OF THE CODE. THE EYE BANK FOLLOWS THE PROVISIONS OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES UNDER THE INCOME TAXES TOPIC OF THE CODIFICATION. THE CODIFICATION REQUIRES THE EYE BANK'S EVALUATION OF TAX POSITIONS, WHICH INCLUDE MAINTAINING ITS TAX-EXEMPT STATUS AND THE TAXABILITY OF ANY UNRELATED BUSINESS INCOME, AND DOES NOT ALLOW RECOGNITION OF TAX POSITIONS WHICH DO NOT MEET A "MORE-LIKELY-THAN-NOT" THRESHOLD OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. MANAGEMENT DOES NOT BELIEVE IT TOOK ANY TAX POSITIONS THAT WOULD NOT MEET THIS THRESHOLD. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON FIXED ASSET DISPOSAL PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON FIXED ASSET DISPOSAL SCHEDULE D, PART XI, LINE 4B THE AMOUNT OF LOSS ON DISPOSAL OF FIXED ASSET WAS REPORTED IN THE EXPENSES FOR FINANCIAL STATEMENT PURPOSES, BUT WAS INCLUDED IN REVENUE FOR TAX PURPOSES. SCHEDULE D, PART XII, LINE 2D THE AMOUNT OF LOSS ON DISPOSAL OF FIXED ASSET WAS REPORTED IN THE EXPENSES FOR FINANCIAL STATEMENT PURPOSES, BUT WAS INCLUDED IN REVENUE FOR TAX PURPOSES. 1 THE UNIVERSITY OF TEXAS HEALTH SAN ANTONIO DEPARTMENT OF OPHTHALMOLOGY 7703 FLOYD CURL DRIVE SAN ANTONIO TX 78229 741586031 501 (C)(3) 0 10000 SUPPORT DEPARTMENT OPHTHALMOLOGY RESIDENTS' TRAINING/EDUCATION PROGRAM 1 PART I, LINE 2: GRANTS ARE PAID DIRECTLY TO COLLEGES AND UNIVERSITIES IN THE UNITED STATES. X 0 0 0 0 0 0 0 0 0 JIM S WAGNER EXECUTIVE DIRECTOR 170478 0 18644 0 3675 0 27000 0 23824 0 243621 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 KENNETH J MAVERICK MD AND JAMES LEHMANN MD - BUSINESS RELATIONSHIP FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS AN INDEPENDENT ACCOUNTING FIRM PREPARES THE FORM 990. THE EXECUTIVE DIRECTOR BASED ON SITE WITH THE REPORTING ORGANIZATION IS PROVIDED THE RETURN PRIOR TO FILING FOR COMMENTS AND REVIEW. THE AUTHORIZED DIRECTOR/OFFICER OF THE GOVERNING BOARD OF DIRECTORS FOR THE REPORTING ORGANIZATION REVIEWS AND SIGNS THE FORM 990 PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 15A PROCESS OF DETERMINING COMPENSATION THE MANAGING ORGANIZATION, CORNEAGEN, IN CONSULTATION WITH THE CHAIRMAN OF THE GOVERNING BOARD OF DIRECTORS OF THE REPORTING ORGANIZATION DETERMINES THE COMPENSATION OF THE EXECUTIVE DIRECTOR AND IN TURN THE MANAGEMENT COMPANY AND THE EXECUTIVE DIRECTOR WILL DETERMINE COMPENSATION LEVELS FOR OTHER INDIVIDUALS STATIONED ONSITE. AN ANNUAL, FORMAL APPRAISAL SYSTEM IS USED TO DETERMINE CHANGES TO COMPENSATION FOR THE EXECUTIVE DIRECTOR AND OTHER STAFF. FORM 990, PART VI, SECTION C, LINE 19 THE REPORTING ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND FINANCIAL INFORMATION AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G REFERRAL SERVICES: PROGRAM SERVICE EXPENSES 120,761. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 120,761. MEDICAL REVIEW: PROGRAM SERVICE EXPENSES 117,122. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 117,122. OPERATIONAL SERVICE FEE TO CORNEAGEN INC: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 240,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 240,000. FORM 990, PART X, LINE 15 IN FEBRUARY 2016, THE FASB ISSUED ACCOUNTING STANDARDS UPDATE 2016-02 LEASES (TOPIC 842) TO INCREASE TRANSPARENCY AND COMPARABILITY AMONG ORGANIZATIONS BY RECOGNIZING LEASE ASSETS AND THE CORRESPONDING LEASE LIABILITIES AND DISCLOSING KEY INFORMATION ABOUT LEASING ARRANGEMENTS FOR LESSEES AND LESSORS. THE NEW STANDARD APPLIES A RIGHT-OF-USE MODEL THAT REQUIRES, FOR ALL LEASES WITH A LEASE TERM OF MORE THAN 12 MONTHS, AN ASSET REPRESENTING ITS RIGHT TO USE THE UNDERLYING ASSET FOR THE LEASE TERM AND A LIABILITY TO MAKE LEASE PAYMENTS TO BE RECORDED. THE ORGANIZATION ADOPTED THE STANDARD EFFECTIVE JULY 1, 2022 AND RECOGNIZED AND MEASURED LEASES EXISTING AT, OR ENTERED INTO AFTER, JULY 1, 2022 THROUGH A CUMULATIVE EFFECT ADJUSTMENT. THE STANDARD HAD A MATERIAL IMPACT ON THE STATEMENT OF FINANCIAL POSITION BUT DID NOT HAVE A MATERIAL IMPACT ON THE STATEMENT OF ACTIVITIES NOR THE STATEMENT OF CASH FLOWS. THE MOST SIGNIFICANT IMPACT WAS THE RECOGNITION OF RIGHT-OF-USE ASSETS AND LEASE LIABILITIES FOR OPERATING LEASES. TO CONFORM WITH FASB AND TO AGREE WITH THE FINANCIAL STATEMENT, THE RIGHT OF USE ASSET HAS BEEN SEPARATELY STATED AS AN OTHER ASSET ON THIS 990. PART XII, LINE 2C THE PROCESS REGARDING THE PREPARATION OF THE AUDITED FINANCIAL STATEMENTS IS UNCHANGED FROM THE PRIOR YEAR.